Stryker Corporation

NYSE:SYK Stock Report

Market Cap: US$136.1b

Stryker Valuation

Is SYK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYK ($364.6) is trading above our estimate of fair value ($358.62)

Significantly Below Fair Value: SYK is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYK?

Key metric: As SYK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SYK. This is calculated by dividing SYK's market cap by their current earnings.
What is SYK's PE Ratio?
PE Ratio38.7x
EarningsUS$3.59b
Market CapUS$136.15b

Price to Earnings Ratio vs Peers

How does SYK's PE Ratio compare to its peers?

The above table shows the PE ratio for SYK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.8x
BSX Boston Scientific
73.1x23.3%US$130.7b
ISRG Intuitive Surgical
83.3x11.4%US$186.6b
MDT Medtronic
24.2x10.2%US$102.6b
ABT Abbott Laboratories
34.5x11.6%US$195.0b
SYK Stryker
38.7x11.6%US$136.1b

Price-To-Earnings vs Peers: SYK is good value based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (53.8x).

Price to Earnings Ratio vs Industry

How does SYK's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.04m
PAVM PAVmed
0.4x-90.0%US$6.65m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
SYK 38.7xIndustry Avg. 35.2xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SYK is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the US Medical Equipment industry average (35.2x).

Price to Earnings Ratio vs Fair Ratio

What is SYK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.7x
Fair PE Ratio36.8x

Price-To-Earnings vs Fair Ratio: SYK is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$364.60
US$406.60
+11.5%
8.0%US$450.00US$276.00n/a28
Dec ’25US$392.15
US$396.81
+1.2%
7.2%US$450.00US$276.00n/a28
Nov ’25US$367.15
US$390.78
+6.4%
7.9%US$420.00US$276.00n/a28
Oct ’25US$357.27
US$373.13
+4.4%
8.3%US$406.00US$260.00n/a28
Sep ’25US$360.42
US$374.04
+3.8%
7.6%US$406.00US$260.00n/a27
Aug ’25US$333.17
US$372.86
+11.9%
8.4%US$406.00US$242.00n/a27
Jul ’25US$336.50
US$372.94
+10.8%
8.4%US$406.00US$242.00n/a26
Jun ’25US$341.09
US$373.07
+9.4%
8.3%US$406.00US$242.00n/a27
May ’25US$328.12
US$371.92
+13.3%
8.5%US$406.00US$242.00n/a26
Apr ’25US$354.67
US$356.76
+0.6%
8.1%US$400.00US$242.00n/a26
Mar ’25US$353.22
US$355.16
+0.5%
8.0%US$400.00US$242.00n/a25
Feb ’25US$340.56
US$350.36
+2.9%
7.8%US$390.00US$242.00n/a25
Jan ’25US$299.46
US$319.44
+6.7%
7.6%US$361.00US$229.00n/a25
Dec ’24US$297.79
US$316.71
+6.4%
7.9%US$361.00US$229.00US$392.1525
Nov ’24US$272.05
US$311.91
+14.7%
8.6%US$345.00US$217.00US$367.1524
Oct ’24US$273.27
US$315.77
+15.6%
8.0%US$345.00US$217.00US$357.2723
Sep ’24US$284.45
US$314.83
+10.7%
8.0%US$345.00US$217.00US$360.4223
Aug ’24US$279.27
US$312.35
+11.8%
8.1%US$345.00US$217.00US$333.1723
Jul ’24US$305.09
US$310.13
+1.7%
8.1%US$345.00US$217.00US$336.5023
Jun ’24US$278.57
US$310.36
+11.4%
8.2%US$345.00US$217.00US$341.0922
May ’24US$299.89
US$287.73
-4.1%
9.9%US$336.00US$200.00US$328.1222
Apr ’24US$285.47
US$277.61
-2.8%
7.5%US$320.00US$200.00US$354.6723
Mar ’24US$259.97
US$275.91
+6.1%
7.0%US$292.00US$200.00US$353.2222
Feb ’24US$278.95
US$272.79
-2.2%
7.5%US$292.00US$200.00US$340.5622
Jan ’24US$244.49
US$245.23
+0.3%
10.2%US$283.00US$197.00US$299.4623
Dec ’23US$240.77
US$236.37
-1.8%
7.9%US$275.00US$197.00US$297.7923

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stryker Corporation is covered by 71 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Richard PurkissAtlantic Equities LLP
Jeffrey JohnsonBaird